<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1646-706X</journal-id>
<journal-title><![CDATA[Angiologia e Cirurgia Vascular]]></journal-title>
<abbrev-journal-title><![CDATA[Angiol Cir Vasc]]></abbrev-journal-title>
<issn>1646-706X</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Angiologia e Cirurgia Vascular]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1646-706X2011000100004</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Carcinoma de Células Renais com Envolvimento Venoso]]></article-title>
<article-title xml:lang="en"><![CDATA[Renal Cell Carcinoma with Venous Involvement]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[Sérgio]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martinho]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendonça]]></surname>
<given-names><![CDATA[Tiago]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernandes]]></surname>
<given-names><![CDATA[Ruy]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Correia]]></surname>
<given-names><![CDATA[Helena]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pedro]]></surname>
<given-names><![CDATA[Luís Mendes]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gama]]></surname>
<given-names><![CDATA[A. Dinis da]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[Tomé]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Centro Hospitalar Lisboa Norte, E.P.E. Hospital de Santa Maria Serviço de Urologia]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Centro Hospitalar Lisboa Norte, E.P.E. Hospital de Santa Maria Clínica Universitária de Cirurgia Vascular]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2011</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2011</year>
</pub-date>
<volume>7</volume>
<numero>1</numero>
<fpage>29</fpage>
<lpage>34</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S1646-706X2011000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S1646-706X2011000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S1646-706X2011000100004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Introdução: O Carcinoma de Células Renais (CCR) representa 3% das neoplasias em adultos. É uma das neoplasias urológicas mais letais, com uma mortalidade específica de 40%. A invasão parietal ou a presença de trombo tumoral na veia cava inferior acontece em 4% a 10% dos doentes (= T3b) com sobrevida estimada aos cinco anos entre 40% e 60%. A única estratégia curativa é a exérese em bloco do trombo tumoral e do rim. Material e Métodos: Avaliámos retrospectivamente os processos clínicos, incluindo dados imagiológicos e histopatológicos, de todos os doentes com CCR submetidos a nefrectomia radical entre 2008 e 2009 na nossa instituição. Resultados: Foi identificado o envolvimento venoso em 10,1% dos doentes (sete em 69), com idade média de 58 anos (32-72). Seis (85,7%) apresentavam invasão da veia renal, quatro (57,1%) trombo tumoral na veia renal e 3 (42,9%) trombo tumoral na veia cava (dois no nível II e um no nível I). A três destes doentes foi realizada cavotomia com excisão do trombo, sem complicações. Um doente abandonou o seguimento médico; dois doentes faleceram no pós-operatório imediato ou precoce (três a sete dias); um doente faleceu por progressão da doença sistémica; os restantes três apresentam progressão da doença. Conclusões: O CCR acompanhado por trombo tumoral na veia cava apresenta uma história natural pouco favorável, mas que pode ser drasticamente alterada se a atitude cirúrgica for agressiva e completa. A constituição de equipas multidisciplinares é fundamental.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Introduction: Renal Cell Carcinoma (RCC) accounts for 3% of adult carcinomas. It is one of the most deadly urological cancers with disease specific mortality of 40%. Venous wall invasion or tumor thrombus is seen in 4% to 10% of patients (= T3b), with 5 years survival from 40% to 60%. The only curative treatment is tumor thrombus and kidney en bloc removal. Materials and Methods: All the clinical, radiological and pathological data of the patients submitted to radical nephrectomy at our institution through 2008 and 2009 was reviewed. Results: We found venous involvement in seven of the 69 patients (10,1%). Average age was 58 years (32-72); Six patients (85,7%) had renal vein invasion; four (57,1%) had renal vein thrombus and three (42,9%) had cava vein thrombus (two at level II and one at level III). Three were submitted to cavotomy with no complications. One was lost to follow-up; two died on early post-op (three to seven days); one died due to systemic disease progression; the other three have disease progression. Conclusions: RCC with vena cava involvement has a poor natural history, but this can be dramatically changed with an aggressive and complete surgical attitude. For that means, multidisciplinary teams are mandatory.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Carcinoma de células renais]]></kwd>
<kwd lng="pt"><![CDATA[veia cava]]></kwd>
<kwd lng="en"><![CDATA[Renal cell carcinoma]]></kwd>
<kwd lng="en"><![CDATA[vena cava]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p><b>Carcinoma de Células Renais com Envolvimento Venoso</b></p>     <p>&nbsp;</p>     <p><b>Sérgio Pereira*, David Martinho*, Tiago Mendonça*, </b><b>Ruy Fernandes**,    Helena Correia*, Luís Mendes Pedro**, </b><b>A. Dinis da Gama**, Tomé Lopes*</b></p>     <p>* Serviço de Urologia</p>     <p>** Clínica Universitária de Cirurgia Vascular Hospital de Santa Maria Centro    Hospitalar Lisboa Norte, E.P.E.</p>     <p><a name="top0"></a><a href="#0">Correspondência</a></p>     <p>&nbsp;</p>     <p>|<b>RESUMO</b>|</p>     <p><i>Introdução:</i> O Carcinoma de Células Renais (CCR) representa 3% das neoplasias    em adultos. É uma das neoplasias urológicas mais letais, com uma mortalidade    específica de 40%. A invasão parietal ou a presença de trombo tumoral na veia    cava inferior acontece em 4% a 10% dos doentes (= T3b) com sobrevida estimada    aos cinco anos entre 40% e 60%. A única estratégia curativa é a exérese em bloco    do trombo tumoral e do rim.</p>     <p><i>Material e Métodos:</i> Avaliámos retrospectivamente os processos clínicos,    incluindo dados imagiológicos e histopatológicos, de todos os doentes com CCR    submetidos a nefrectomia radical entre 2008 e 2009 na nossa instituição.</p>     ]]></body>
<body><![CDATA[<p><i>Resultados:</i> Foi identificado o envolvimento venoso em 10,1% dos doentes    (sete em 69), com idade média de 58 anos (32-72). Seis (85,7%) apresentavam    invasão da veia renal, quatro (57,1%) trombo tumoral na veia renal e 3 (42,9%)    trombo tumoral na veia cava (dois no nível II e um no nível I). A três destes    doentes foi realizada cavotomia com excisão do trombo, sem complicações. Um    doente abandonou o seguimento médico; dois doentes faleceram no pós-operatório    imediato ou precoce (três a sete dias); um doente faleceu por progressão da    doença sistémica; os restantes três apresentam progressão da doença.</p>     <p><i>Conclusões:</i> O CCR acompanhado por trombo tumoral na veia cava apresenta    uma história natural pouco favorável, mas que pode ser drasticamente alterada    se a atitude cirúrgica for agressiva e completa. A constituição de equipas multidisciplinares    é fundamental.</p>     <p><b>Palavras-chave:</b> Carcinoma de células renais, veia cava,</p>     <p>&nbsp;</p>     <p><b>Renal Cell Carcinoma with Venous Involvement</b></p>     <p>|<b>ABSTRACT</b>|</p>     <p><i>Introduction:</i> Renal Cell Carcinoma (RCC) accounts for 3% of adult carcinomas.    It is one of the most deadly urological cancers with disease specific mortality    of 40%. Venous wall invasion or tumor thrombus is seen in 4% to 10% of patients    (= T3b), with 5 years survival from 40% to 60%. The only curative treatment    is tumor thrombus and kidney en bloc removal.</p>     <p><i>Materials and Methods:</i> All the clinical, radiological and pathological    data of the patients submitted to radical nephrectomy at our institution through    2008 and 2009 was reviewed.</p>     <p><i>Results:</i> We found venous involvement in seven of the 69 patients (10,1%).    Average age was 58 years (32-72); Six patients (85,7%) had renal vein invasion;    four (57,1%) had renal vein thrombus and three (42,9%) had cava vein thrombus    (two at level II and one at level III). Three were submitted to cavotomy with    no complications. One was lost to follow-up; two died on early post-op (three    to seven days); one died due to systemic disease progression; the other three    have disease progression.</p>     <p><i>Conclusions:</i> RCC with vena cava involvement has a poor natural history,    but this can be dramatically changed with an aggressive and complete surgical    attitude. For that means, multidisciplinary teams are mandatory.</p>     ]]></body>
<body><![CDATA[<p><b>Key words:</b> Renal cell carcinoma, vena cava</p>     <p>&nbsp;</p>     <p>Texto completo disponível apenas em PDF.</p>     <p>Full text only available in PDF format.</p>     <p>&nbsp;</p>     <p><b>BIBLIOGRAFIA</b></p>     <p><sup>[1]</sup> Börje Ljungberg, et al; EAU Guidelines on Renal Cell Carcinoma:    The 2010 Update; European Urology 58 (2010) 398-406</p>     <p><sup>[2]</sup> Wein, Kavoussi, Novick, Partin, Peters; Campbell-Walsh Urology    9th ed; 2007; Saunders</p>     <p><sup>[3]</sup> Fernando Alonso, et al; Renal cell carcinooma with vana cava    involvement: update and review of our series; Actas Urológicas Españolas 2009;    33 (5): 569-74</p>     <!-- ref --><p><sup>[3]</sup> S H Landis, et al; Cancer statistics; CA Cancer J Clin; 1999;    49 (1): 8-31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000032&pid=S1646-706X201100010000400001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><sup>[4]</sup> J Ferlay, et al; Estimates of the câncer incidence and mortality    in Europe in 2006; Ann Oncol 2007 Mar; 18 (3): 581-92</p>     <p><sup>[5]</sup> L Lipworth, et al; The epidemiology of renal cell carcinoma.    J Urol 2006; Dec; 176 (6 Pt 1): 2353-8</p>     <p><sup>[6]</sup> W H Chow, et al; Rising incidence of renal cell câncer in the    United States; JAMA 1999; 281: 1628-1631</p>     <p><sup>[7]</sup> C T Lee, et al; Mode of presentation of renal cell carcinoma    provides prognostic information; Urol Oncol 2002 Jul-Aug;7(4):135-40</p>     <p><sup>[8]</sup> J J Patard, et al; Correlation between symptom graduation, tumor    characteristics and survival in renal cell carcinoma; Eur Urol 2003 Aug;44(2):226-32</p>     <p><sup>[9]</sup> C J Kane, et al; Renal cell cancer stage migration: analysis    of the National Cancer Data Base; Cancer 2008 Jul;113(1):78-83.</p>     <p><sup>[10]</sup> H L Kim, et al; Paraneoplastic signs and symptoms of renal    cell carcinoma: implications for prognosis; J Urol 2003 Nov;170(5):1742-6</p>     <p><sup>[11]</sup> R M Bukowski; Natural history and therapy of metastatic renal    cell carcinoma: the role of interleukin-2; Cancer 1997; 80:1198-1220</p>     <p><sup>[12]</sup> Mohammed Al Otaibi, et al; Locally advanced renal cell carcinoma;    Canadian Urological Association Journal; 2007; 1 (2): S55-S61</p>     <p><sup>[13]</sup> O D Garcia, et al; Surgical stratification of renal carcinoma    with extension into inferior vena cava; Actas Urol Esp; 2005; 29 (5); 448-456</p>     ]]></body>
<body><![CDATA[<p><sup>[14]</sup> Robert J Motzer, et al; National Comprehensive Cancer Network    clinical practice guidelines in oncology – Kidney Cancer V.2.2010; <a href="http://www.nccn.org" target="_blank">www.nccn.org</a></p>     <p><sup>[15]</sup> D A Goldfarb, et al; Magnetic resonance imaging for assessment    of vena caval tumor thrombi: a comparative study with venocavography and computerized    tomography scanning; J Urol 1990; 144: 1100-3</p>     <p><sup>[16]</sup> N Lawrentschuk, et al; Multidetector computed tomography vs    magnetic resonante imaging for defining tthe upper limito f tumour thrombus    in renal cell carcinoma: a study and review; BJU Int 2005; 96 (3) 291-295</p>     <p><sup>[17]</sup> P J Hallscheidt, et al; Preoperative staging of renal cell    carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective    study with histopathological correlation; J Comput Assist Tomogr 2005; 29: 64-8</p>     <p><sup>[18]</sup> J Rioja Zuazu, et al; Extracorporeal circulation and hypothermy    surgery in tumors with vena cava extension: 20 years experience at the University    Clinic of Navarra; Actas Urol ESp; 2008; 32 (4): 396-405</p>     <p><sup>[19]</sup> M L Blute, et al; The Mayo Clinic experience with surgical    management complications ant outcome for patients with renal cell carcinoma    and venous tumour thrombus; BJU Int 2004; 94: 33-41</p>     <p><sup>[20]</sup> G Ciancio, et al; Surgical management of renal cell carcinoma    with tumor thrombus in the renal and inferior vena cava: the University of Miami    experience in using liver transplantation techniques; Eur Urol; 2007; 51 (4);    988-995</p>     <p><sup>[21]</sup> M Gallucci, et al; Liver harvesting surgical technique for    the treatment of retro-hepatic caval thrombosis concomitant to renal cell carcinoma:    prerioperative and long-term results in 15 patients without mortality; Eur Urol    2004; 45: 194-202</p>     <p><sup>[22]</sup> M Jibiki, et al; Surgical strategy for treating a renal neoplasm    invading the inferior vena cava; J Vasc Surg 2004; 39: 829-35</p>     <p><sup>[23]</sup> American Cancer Society; Cancer Facts &amp; Figures 2010; Atlanta;    American Cancer Society; 2010</p>     ]]></body>
<body><![CDATA[<p><sup>[24]</sup> V Ficarra, W Artibani; Staging system of renal cell carcinoma:    cirrent issues; Eur Urol 2006; 49: 223-5</p>     <p><sup>[25]</sup> R H Thompson, et al; Reclassification of patients with pT3    and pT4 renal cell carcinoma improves prognostic accuracy; Cancer 2005; 104:    53-60</p>     <p>&nbsp;</p>     <p><a name="0"></a><a href="#top0">Correspondência</a>: Sérgio Pereira <a href="mailto:sahpereira@sapo.pt">sahpereira@sapo.pt</a>    965616911</p>     <p><b>Apresentado no X Congresso Anual da Sociedade Portuguesa de Angiologia e    Cirurgia Vascular – 02 a 05 de Junho de 2010</b></p>      ]]></body><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Landis]]></surname>
<given-names><![CDATA[S H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cancer statistics]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>1999</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>8-31</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
